In December 2025, 74 drug samples were identified as Not of Standard Quality (NSQ) by Central Drugs Laboratories and 93 by State Drugs Testing Laboratories. Additionally, seven spurious drug samples were identified across various zones, manufactured by unauthorized entities. These findings are part of routine regulatory surveillance to ensure market safety.
